OncoMatch/Clinical Trials/NCT04477343
A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Is NCT04477343 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including SX-682 and Nivolumab Injectable Product for pancreatic ductal adenocarcinoma.
Treatment: SX-682 · Nivolumab Injectable Product — The main purpose of this research study is to determine the maximum tolerable dose (MTD) of SX-682 in combination with nivolumab in patients with metastatic pancreatic ductal adenocarcinoma who have completed at least 16 weeks of first line chemotherapy treatment without evidence of disease progression.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy — first line
Completion of at least 16 weeks of first line chemotherapy without evidence of disease progression
Cannot have received: immunotherapy
Patients who received immunotherapy or investigational drug within 4 weeks prior to enrollment
Cannot have received: investigational drug
Use of other investigational drugs (drugs not marketed for any indication) or medications at immunosuppressive doses within 28 days before study drug administration
Lab requirements
Blood counts
WBC ≥ 3000/µL; Neutrophils ≥ 1500/µL; Platelets ≥ 100,000/µL; Hemoglobin ≥ 9.0 g/dL in the absence of blood transfusion
Kidney function
Creatinine ≤ 1.5 mg/dL
Liver function
AST/ALT ≤ 2.5 x ULN for subjects with no liver metastases; ≤ 5 x ULN for subjects with liver metastases; Bilirubin ≤ 1.5 mg/dL or ≤ 3.0 mg/dL for subjects with Gilbert's disease
Screening laboratory values within 14 days prior to first dose of study drug: WBC ≥ 3000/µL Neutrophils ≥ 1500/µL Platelets ≥ 100,000/µL Hemoglobin ≥ 9.0 g/dL in the absence of blood transfusion Creatinine ≤ 1.5 mg/dL AST/ALT ≤ 2.5 x ULN for subjects with no liver metastases * 5 x ULN for subjects with liver metastases Bilirubin ≤ 1.5 mg/dL ≤ 3.0 mg/dL for subjects with Gilbert's disease INR or PT ≤ 1.5 x ULN unless receiving anticoagulation therapy aPTT or PTT ≤ 1.5 x ULN unless receiving anticoagulation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Rochester · Rochester, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify